Article in Molecular pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 1 institution in 2 countries.
William A MurphyDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (W.A.M., J.J.B., N.S., M.M.M., H.H., P.H., K.L.R.B.); School of Pharmacy, University of Eastern Finland, Kuopio, Finland (T.L., M.M.M., P.H.); and Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (P.W.S.).ORCID 0000-0002-7476-9248
James J BeaudoinDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (W.A.M., J.J.B., N.S., M.M.M., H.H., P.H., K.L.R.B.); School of Pharmacy, University of Eastern Finland, Kuopio, Finland (T.L., M.M.M., P.H.); and Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (P.W.S.).ORCID 0000-0002-6926-8844
Tuomo LaitinenDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (W.A.M., J.J.B., N.S., M.M.M., H.H., P.H., K.L.R.B.); School of Pharmacy, University of Eastern Finland, Kuopio, Finland (T.L., M.M.M., P.H.); and Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (P.W.S.).ORCID 0000-0003-1539-2142
Noora SjöstedtDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (W.A.M., J.J.B., N.S., M.M.M., H.H., P.H., K.L.R.B.); School of Pharmacy, University of Eastern Finland, Kuopio, Finland (T.L., M.M.M., P.H.); and Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (P.W.S.).ORCID 0000-0001-6960-7757
Melina M MalinenDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (W.A.M., J.J.B., N.S., M.M.M., H.H., P.H., K.L.R.B.); School of Pharmacy, University of Eastern Finland, Kuopio, Finland (T.L., M.M.M., P.H.); and Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (P.W.S.).ORCID 0000-0002-9955-5043
Henry HoDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (W.A.M., J.J.B., N.S., M.M.M., H.H., P.H., K.L.R.B.); School of Pharmacy, University of Eastern Finland, Kuopio, Finland (T.L., M.M.M., P.H.); and Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (P.W.S.).ORCID 0000-0003-1138-9149
Peter W SwaanDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (W.A.M., J.J.B., N.S., M.M.M., H.H., P.H., K.L.R.B.); School of Pharmacy, University of Eastern Finland, Kuopio, Finland (T.L., M.M.M., P.H.); and Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (P.W.S.).ORCID 0000-0003-1767-1487
Paavo HonkakoskiDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (W.A.M., J.J.B., N.S., M.M.M., H.H., P.H., K.L.R.B.); School of Pharmacy, University of Eastern Finland, Kuopio, Finland (T.L., M.M.M., P.H.); and Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (P.W.S.) kbrouwer@unc.edu paavo.honkakoski@uef.fi.ORCID 0000-0002-4332-3577
Kim L R BrouwerDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (W.A.M., J.J.B., N.S., M.M.M., H.H., P.H., K.L.R.B.); School of Pharmacy, University of Eastern Finland, Kuopio, Finland (T.L., M.M.M., P.H.); and Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (P.W.S.) kbrouwer@unc.edu paavo.honkakoski@uef.fi.ORCID 0000-0003-1945-4929
University of North Carolina at Chapel Hill · US
Funding
Mechanisms of Altered Hepatic Transport: Impact on Drug TherapyR35GM122576 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER · 2017 to 2026
$5.7M
Structural Biology of the Apical Bile Acid Transporter.R01DK061425 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI SWAAN, PETER W · 2003 to 2020
$4.6M
Elucidating the Role of Organic Solute Transporter (OST) Alpha/Beta in Bile Acid Transport and Drug InteractionsF31DK120196 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BEAUDOIN, JAMES JOHN · 2019 to 2020
Organic solute transporter α/β (OSTα/β) is a bidirectional bile acid transporter localized on the basolateral membrane of hepatic, intestinal, and renal epithelial cells. OST
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Identification of Key Amino Acids that Impact Organic Solute Transporter · full record | OpenQuestion